The Spanish Association of Orphan and Ultra-Orphan Drug Laboratories (AELMHU) celebrates its 15th anniversary today, a milestone that reaffirms the commitment of pharmaceutical companies dedicated to researching and developing treatments for people with rare diseases.
Since January 14, 2011, when three companies (Shire, Alexion, and Orphan Europe) decided to join forces to create the association, AELMHU has continued to grow. Fifteen years later, thanks to the work and involvement of all its members, it has established itself as a recognized player in the healthcare sector, driving innovation, promoting research, and generating knowledge about rare diseases.
Throughout 2026, the association will celebrate this anniversary with various commemorative activities and content, which will highlight its achievements, showcase the work carried out over the last fifteen years, and reinforce AELMHU's role in the field of rare diseases.
The first of these actions was published today on the association's social media accounts, under the hashtag #JuntosporlasRaras(Together for Rare Diseases), with a video reviewing the key areas in which AELMHU works and sending a message of unity to all stakeholders in the rare diseases sector to continue advancing in the approach to these pathologies.
Collaboration has been one of the cornerstones of the association since its inception. AELMHU has worked closely with healthcare professionals, public administrations, patient associations, and numerous entities in the health sector, with the common goal of ensuring that scientific advances reach those who need them most.
The association begins this anniversary year with renewed energy, ready to continue moving forward with the same spirit that has guided its work since day one and with the conviction to continue improving the lives of people with rare diseases.
Many thanks to our partners and to everyone who has accompanied us during this time. Your trust and constant support have been fundamental in building what AELMHU is today. Every step taken, every project promoted, and every advance achieved has been possible thanks to the combined efforts of those who have believed in this collective mission. We will continue to work with the same dedication to live up to that shared commitment.
